Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/4965—Non-condensed pyrazines
  • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
  • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
  • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
  • A01N43/60—1,4-Diazines; Hydrogenated 1,4-diazines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P33/00—Antiparasitic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P33/00—Antiparasitic agents
  • A61P33/14—Ectoparasiticides, e.g. scabicides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Definitions

• This application relates to active ingredient combinations of pyrazine-2-yl-pyrazoles (component A) with at least one further ectoparasiticide or synergist (component B), as well as products containing such drug combinations. These drug combinations are suitable for controlling animal pests in the veterinary field.
• WO 2007 / 048733A describes the use of aminopyrazoles for controlling plant-pathogenic harmful fungi, whereby pyrazine-2-yl-pyrazoles are also generically included.
• the pyrazine-2-yl-pyrazoles carry only hydrogen as a substituent in the 3-position.
• WO 2007 / 027842A discloses anilinopyrazoles which may be substituted in the 1-position of the pyrazole unit by 2-pyrazines. This international application relates to pharmaceutical applications, in particular to the treatment of diabetes; an arthropodizide effect is not described.
• the object of the present invention is thus to provide alternative insecticides and / or parasiticidal products which show an improved action or a broadened spectrum of activity compared with the active compounds known from the prior art, in particular in an increasing combination with further veterinary medicinally known ectoparasiticides or synergists.
• the active ingredients mentioned in this specification with their "common name” are known, for example, from “The Pesticide Manual” 14th Ed., British Crop Protection Council 2006, and the website http: // www. alanwood.net/pesticides known.
• active ingredient combinations comprising as component A certain pyrazine-2-yl-pyrazoles and as component B a further ectoparasitziden active substance have very good veterinary medically important ectoparasiticidal effects.
• the invention therefore relates to products comprising as component A a compound of the general formula (I)
• X is phenyl, 2-pyridyl or 3-pyridyl, each of which is substituted by one or more substituents selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, alkoxyalkyl, alkoxyalkoxy, cycloalkyl, alkenyloxy, alkynyloxy, benzyloxy, Cycloalkylalkoxy, haloalkoxy, haloalkoxyalkyl, alkylsulfanyl, haloalkylsulfanyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, cyano, nitro, alkylcarbonyl, alkoxycarbonyl, alkoxycarbonylalkyl, carboxyl, carboxamide, dialkylcarboxamide, trialkylsilyl, amino, alkylamino
• R 1 is alkyl which is optionally monosubstituted or independently substituted several times by alkoxy, haloalkoxy, alkylsulfanyl, haloalkylsulfanyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, alkoxycarbonyl, hydroxy and / or cycloalkyl; Alkenyl, which is optionally monosubstituted or disubstituted by a plurality of halogen, alkoxy, haloalkoxy, alkylsulfanyl, haloalkylsulfanyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, Haloalkylsulfonyl, alkylcarbonyl, alkoxycarbonyl, and /
• R 2 is optionally substituted amino wherein amino may be monosubstituted or independently substituted with alkyl, haloalkyl, alkoxyalkyl, alkylsulfanylalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, alkylcarbonyl, cycloalkyl, cycloalkylalkyl, alkenyl wherein the above radicals are optionally substituted by halogen , Cyano, alkoxy, alkoxycarbonyl and phenyl, wherein the phenyl ring is optionally mono- or polysubstituted with one or more substituents independently selected from halogen, alkyl, haloalkyl and alkoxy; Alkynyl, alkoxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl, alkoxycarbonylalkyl, alkoxycarbonylcarbonyl, heterocyclyl, heteroary
• -C (CH 3 ) NO-alkyl
• -C (CH 3 ) NO-haloalkyl, nitro, hydroxy, SH, alkoxy, alkylsulfanyl, haloalkylsulfanyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl or haloalkylsulfonyl;
• R 5 is halogen, alkyl, haloalkyl, hydroxy, alkoxy, alkoxyalkyl, alkoxyalkoxy, cycloalkyl, alkenyloxy, alkynyloxy, benzyloxy, cycloalkylalkoxy, haloalkoxy, haloalkoxyalkyl, -SH, alkylsulfanyl, haloalkylsulfanyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, cyano, nitro, Alkylcarbonyl, alkoxycarbonyl, alkoxycarbonylalkyl, carboxyl, carboxamide, Dialkylcarboxamide, trialkylsilyl, nitro, amino, alkylamino, dialkylamino, alkylsulfonylamino, dialkylsulfony
• X is phenyl, 2-pyridyl or 3-pyridyl, each of which is substituted by one or more substituents selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, alkylsulfanyl, Haloalkylsulfanyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, cyano, nitro, dialkylamino; and optionally substituted with one or more halogen atoms, cyano, nitro, alkyl, alkoxy or haloalkyl Phenyl, 2-pyridyl and 3-pyridyl, wherein vicinal alkyl, haloalkyl and / or alkoxy groups on the phenyl substituent, 2-pyridyl substituents or 3-pyridyl, wherein
• X is phenyl, 2-pyridyl or 3-pyridyl, each of which is substituted by one or more substituents selected from the group consisting of halo, alkyl, haloalkyl, alkoxy, haloalkoxy, alkylsulfanyl , Haloalkylsulfanyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, cyano and dialkylamino; and phenyl optionally substituted with one or more halogen atoms, cyano, nitro, alkyl, alkoxy or haloalkyl, 2-pyridyl and 3-pyridyl, vicinal alkyl, haloalkyl and / or alkoxy groups on the phenyl substituent, 2-pyridyl substituents or 3-pyridyl substitu
• substituents selected
• radical X is phenyl, 2-pyridyl or 3-pyridyl, which are each substituted by one or more substituents selected from the group consisting of fluorine, chlorine, bromine, iodine, CF3 , Methoxy, ethoxy, trifluoroethoxy, methylsulfanyl, 2,2,2-trifluoroethylsulfanyl, methylsulfinyl, 2,2,2-trifluoroethylsulfinyl, methylsulfonyl, 2,2,2-trifluoroethylsulfonyl, cyano and dimethylamino; and phenyl optionally substituted with one or more halogen atoms, cyano, nitro, methyl, methoxy or CF 3, wherein vicinal alkyl or alkoxy groups on the phenyl substituent together with the carbon atoms to which they are attached may form a five- or six-
• radical X is phenyl which is substituted on up to three carbon atoms by substituents selected from the group consisting of chlorine, alkoxy having up to 4 carbon atoms (for example methoxy or ethoxy), Di (Ci-4) -alkylamino (eg dimethylamino) and the group via the oxygen atoms with two vicinal carbon atoms of the phenyl ring connected group -O-CH2-O-; for example, X is 7-chloro-1,3-benzodioxol-5-yl; 3, 5-dichloro-4-methoxyphenyl; 3, 5-dichloro-4-dimethylamino-phenyl.
• substituents selected from the group consisting of chlorine, alkoxy having up to 4 carbon atoms (for example methoxy or ethoxy), Di (Ci-4) -alkylamino (eg dimethylamino) and the group via the oxygen atoms with two vicinal carbon atoms
• radical R 1 is alkyl which is optionally monosubstituted or independently substituted several times by alkoxy, haloalkoxy, alkylsulfanyl, haloalkylsulfanyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, alkoxycarbonyl, hydroxy and / or cycloalkyl; Alkenyl which is optionally monosubstituted or independently substituted a plurality of halogen, alkoxy, haloalkoxy, alkylsulfanyl, haloalkylsulfanyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylcarbonyl, alkoxycarbonyl, alkoxycarbonyl
• radical R 1 is CF 3.
• R 2 is amino and substituted amino, where the substituted amino may be monosubstituted or disubstituted by alkyl, haloalkyl, cycloalkylalkyl, optionally by Halogen or phenyl-substituted alkenyl, alkynyl, heterocyclylalkyl and / or heteroarylalkyl, wherein the heteroaromatic ring may optionally be monosubstituted or polysubstituted with one or more substituents independently selected from halogen, alkyl, haloalkyl and alkoxy; Benzyl, wherein the phenyl ring in the benzyl may optionally be mono- or polysubstituted with one or more substituents independently selected from halogen, alkyl, haloalkyl and alkoxy;
• radical R 2 is amino and substituted amino, wherein the substituted amino may be monosubstituted or independently substituted with alkyl, optionally substituted by halogen or phenyl alkenyl, alkynyl, heteroarylalkyl, wherein the heteroaromatic ring optionally mono- or polysubstituted may be substituted with one or more substituents independently selected from halogen and / or alkyl; Benzyl, where the phenyl ring in benzyl may optionally be monosubstituted or polysubstituted with one or more substituents independently selected from halogen and alkoxy;
• radical R 2 is amino, methylamino, dimethylamino, benzylamino, dibenzylamino, (4-chlorobenzyl) amino, bis (4-chlorobenzyl) amino, (4-methoxybenzyl) -amino, bis (4- methoxybenzyl) amino, (2-methylprop-2-en-1-yl) amino, prop-2-en-1-ylamino, prop-2-yn-1-ylamino, bis (prop-2-yn-1-yl ) amino, (pyrazino-2-ylmethyl) amino, (6-methylpyridin-2-ylmethyl) amino, bis (6-methylpyridin-2-ylmethyl) amino and (pyridin-2-ylmethyl) amino; Of these, in turn, particularly preferably, the radical R 2 is amino (-NH 2).
• compounds of the general formula (I) are amino, methylamino, dimethylamino, benzylamino, dibenzylamino, (4-chlorobenz
• radicals R 3 and R 4 independently of one another represent hydrogen, halogen, alkyl, cycloalkyl, haloalkyl, cyano and / or hydroxy;
• radicals R 3 and R 4 independently of one another represent hydrogen, halogen and / or alkyl
• radicals R 3 and R 4 independently of one another represent hydrogen, chlorine and / or methyl
• the radical R 5 is halogen, alkyl, haloalkyl, hydroxy, alkoxy, haloalkoxy, alkylsulfanyl, haloalkylsulfanyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, cyano, amino, alkylamino, dialkylamino, alkylsulfonylamino, dialkylsulfonylamino, heteroaryl, optionally wherein the heteroaromatic ring is simple or may be poly-substituted with one or more substituents independently selected from halo, alkyl, haloalkyl and alkoxy;
• radical R 5 is halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, alkylsulfanyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, cyano, dialkylamino or heteroaryl, where the heteroaromatic ring may be optionally mono- or polysubstituted with a or a plurality of substituents independently selected from halogen and alkyl; and
• radical R 5 represents chlorine, bromine, methyl, CF 3, methoxy, ethoxy, propoxy, propan-2-yloxy, dimethylamino, cyano, methylsulfanyl, methylsulfinyl, methylsulfonyl, lH-pyrazol-1-yl , 1H-imidazol-1-yl, and 4-fluoro-1H-pyrazol-1-yl; stands; (D) very particularly preferably, in which the radical R 5 is methoxy or in particular ethoxy.
• the compound of general formula (I) also includes compounds which are quaternized by a) protonation, b) alkylation or c) oxidation on a nitrogen atom.
• the compounds of general formula (I) may optionally be prepared by addition of a suitable inorganic or organic acid, such as HCl, HBr, H2SO4 or HNO3, but also oxalic acid or sulfonic acids to a basic group, such.
• a suitable inorganic or organic acid such as HCl, HBr, H2SO4 or HNO3, but also oxalic acid or sulfonic acids to a basic group, such.
• amino or alkylamino salts.
• Suitable substituents which are in deprotonated form such as.
• sulfonic acids or carboxylic acids internal salts may in turn form protonatable groups, such as amino groups.
• Salts may also be formed by reacting with suitable substituents, such as. As sulfonic acids or carboxylic acids, the hydrogen is replaced by a cation suitable in the pharmaceutical field.
• suitable substituents such as.
• sulfonic acids or carboxylic acids the hydrogen is replaced by a cation suitable in the pharmaceutical field.
• These salts are, for example, metal salts, in particular alkali metal salts or alkaline earth metal salts, in particular sodium and potassium salts, or ammonium salts, salts with organic amines or quaternary (quaternary) ammonium salts with cations of the formula [NRR'R "R" '] +, where R to R each independently represent an organic radical, in particular alkyl, aryl, aralkyl or alkylaryl.
• radicals alkyl, alkoxy, haloalkyl, haloalkoxy, alkylamino, alkylsulfinyl and alkylsulfonyl, and the corresponding unsaturated and / or substituted radicals in the carbon skeleton may each be straight-chain or branched.
• these radicals are the lower carbon skeletons, e.g. B. with 1 to 6 carbon atoms, in particular 1 to 4 carbon atoms, or in the case of unsaturated groups having 2 to 6 carbon atoms, in particular 2 to 4 carbon atoms, is preferred.
• Alkyl radicals including in the composite meanings such as alkoxy, haloalkyl, etc., mean, for. Methyl; ethyl; Propyl, such as n- or i-propyl; Butyl, such as n-, i-, t- or 2-butyl; Pentyl such as n-pentyl, iso-pentyl and neo-pentyl; Hexyl such as n-hexyl, i-hexyl, 3-methylpentyl, 2,2-dimethylbutyl and 2,3-dimethylbutyl; and heptyl such as n-heptyl, 1-methylhexyl and 1,4-dimethylpentyl; Alkenyl and alkynyl radicals have the meaning of the possible unsaturated radicals corresponding to the alkyl radicals; wherein at least one double bond or triple bond, preferably a double bond or triple bond is included.
• Alkenyl means z. Vinyl, 1-allyl, 1-methylprop-2-en-1-yl, 2-methyl-prop-2-en-1-yl, but-2-en-1-yl, but-3-ene 1-yl, 1-methylbut-3-en-1-yl and 1-methylbut-2-en-1-yl; Alkynyl means z. Ethynyl, propargyl / propynyl, but-2-yn-1-yl, but-3-yn-1-yl and 1-methyl-but-3-yn-1-yl.
• Cycloalkyl groups are, for. Cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
• the cycloalkyl groups can occur in bi- or tri-cyclic form.
• haloalkyl groups and haloalkyl groups of haloalkoxy, haloalkenyl, haloalkynyl and the like are mentioned. are indicated in these residues, the lower carbon skeletons, z. B. with 1 to 6 carbon atoms or 2 to 6, in particular 1 to 4 carbon atoms or preferably 2 to 4 carbon atoms, and the corresponding unsaturated and / or substituted radicals in the carbon skeleton in each case straight-chain or branched. Examples are trifluoromethyl, difluoromethyl, 2,2,2-trifluoroethyl, trifluoroallyl and 1-chloroprop-1-yl-3-yl.
• Alkylene groups in these residues are the lower carbon skeletons, e.g. B. having 1 to 10 carbon atoms, in particular 1 to 6 carbon atoms or preferably 2 to 4 carbon atoms, and the corresponding unsaturated and / or substituted radicals in the carbon skeleton, which may each be straight-chain or branched. Examples are methylene, ethylene, n- and i-propylene and n-, s-, i-, t-butylene. Hydroxyalkyl groups in these residues are the lower carbon skeletons, e.g. B.
• Halogen is fluorine, chlorine, bromine or iodine, haloalkyl, alkenyl and alkynyl by halogen, preferably by fluorine, chlorine or bromine, in particular by fluorine and / or chlorine, partially or fully substituted alkyl, alkenyl or alkynyl, z.
• Haloalkoxy is z.
• Aryl means a mono-, bi- or polycyclic aromatic system, for example phenyl or naphthyl, preferably phenyl.
• polycyclic systems are also included, for example 8-aza-bicyclo [3.2.1] octanyl or 1-azabicyclo [2.2.1] heptyl.
• spirocyclic systems are also included, such as, for example, 1-oxa-5-aza-spiro [2.3] hexyl.
• the heterocyclic ring preferably contains 3 to 9 ring atoms, in particular 3 to 6 ring atoms, and one or more, preferably 1 to 4, in particular 1, 2 or 3 heteroatoms in the heterocyclic ring, preferably from the group consisting of N , O, and S, but not two oxygen atoms should be directly adjacent.
• heteroaryl is understood in the context of the present invention as defined above under “heterocyclyl” but which are heteroaromatic, d. H. represent a fully unsaturated aromatic heterocyclic compound.
• substituted by one or more radicals means, independently of one another, one or more identical or different radicals, it being possible for two or more radicals to form one or more rings on one cycle as main body.
• a substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, phenyl, benzyl, heterocyclyl and heteroaryl radical mean, for example, a substituted radical derived from the unsubstituted radical, where the substituents are, for example, one or more preferably 1, 2 or 3 radicals from the group halogen, alkoxy, alkylthio, hydroxy, amino, nitro, carboxy or a carboxy group equivalent group, cyano, isocyano, azido, alkoxycarbonyl, alkylcarbonyl, formyl, carbamoyl, mono- and dialkylaminocarbonyl, substituted amino, such as acyla
• substituents in addition to the said saturated hydrocarbon-containing radicals corresponding unsaturated aliphatic and aromatic radicals such as optionally substituted alkenyl, alkynyl, alkenyloxy, alkynyloxy, alkenylthio, alkynylthio, alkenyloxycarbonyl, alkynyloxycarbonyl, alkenylcarbonyl, alkynyl - carbonyl, mono- and dialkenylaminocarbonyl, mono- and dialkynylaminocarbonyl, mono- and dialkenylamino, mono- and dialkynylamino, trialkenylsilyl, trialkynylsilyl, optionally substituted cycloalkenyl, optionally substituted cycloalkynyl, phenyl, phenoxy, etc., included.
• cyclic systems are also included with such substituents attached to the ring with a double bond, e.g. B. substituted with an alkylidene group such as methylidene or ethylidene or an oxo group, imino group or substituted imino group.
• radicals form one or more rings, these may be carbocyclic, heterocyclic, saturated, partially saturated, unsaturated, for example also aromatic and optionally further substituted.
• the fused rings are preferably 5- or 6-membered rings, particularly preferred are benzo-fused rings.
• first substituent level if they contain hydrocarbon-containing moieties, may optionally be further substituted there (“second substituent level”), for example by one of the substituents as defined for the first substituent level.
• second substituent level may optionally be further substituted there
• substituent levels are possible.
• substituted radical includes only one or two substituent levels.
• Preferred substituents for the substituent levels are, for example, amino, hydroxy, halogen, nitro, cyano, isocyano, mercapto, isothiocyanato, carboxy, carbonamide, SF5, aminosulfonyl, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, monoalkylamino, dialkylamino, N Alkanoylamino, alkoxy, alkenyloxy, alkynyloxy, cycloalkoxy, cycloalkenyloxy, alkoxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl, aryloxycarbonyl, alkanoyl, alkenylcarbonyl, alkynylcarbonyl, aryl carbonyl, alkylthio, cycloalkylthio, alkenylthio, cycloalkenylthio, alkynylthio
• radicals having carbon atoms are preferably those having 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms, in particular 1 or 2 carbon atoms.
• substituents from the group halogen are preferred, for. Fluoro, chloro and bromo, (C 1 -C 4) -alkyl, preferably methyl or ethyl, (C 1 -C 4) -haloalkyl, preferably trifluoromethyl, (C 1 -C 4) -alkoxy, preferably methoxy or ethoxy, (C 1 -C 4) Haloalkoxy, nitro and cyano.
• Optionally substituted aryl or heteroaryl is preferably phenyl or heteroaryl which is unsubstituted or monosubstituted or polysubstituted, preferably up to three times by identical or different radicals from the group consisting of halogen, (C 1 -C 4) -alkyl, (C 3 -C 6) -cycloalkyl, (C 1 -C 4) -Alkoxy, (C 1 -C 4) -halogenoalkyl, (C 1 -C 4) -haloalkoxy, (C 1 -C 4) -alkylthio, cyano and nitro, eg. B.
• the compounds of the invention may optionally be used as mixtures of various possible isomeric forms, in particular of stereoisomers, such as. B. E and Z, threo and erythro, and optical isomers, but optionally also of tautomers. Both the E and the Z isomers, as well as the threo and erythro, and the optical isomers, any mixtures of these isomers, as well as the possible tautomeric forms claimed.
• A-2 4- (7-C or-1, 3-benzodioxol-5-yl) -1- (3-methoxypyrazino-2-yl) -3- (trmuomethyl) -1H-pyrazole-5-amm
• A-3 4- (7-C or-1, 3-benzodioxol-5-yl) -1- (3-methoxypyrazino-2-yl) -3-methyl-1H-pyrazol-5-amine
• A-4 (7-chloro-1, 3-benzodioxol-5-yl) -1- (3-ethoxypyrazino-2-yl) -3-ethyl-1H-pyrazol-5-amine
• A-5 4- (7-C or-1, 3-benzodioxol-5-yl) -1- (3-methoxypyrazino-2-yl) -3-ethyl-1H-pyrazol-5-amine
• A-6 4- (7-C or-1, 3-benzodioxol-5-yl) -1- (3-methoxypyrazino-2-yl) -3-isopropyl-1H-pyrazol-5-amine
• A-7 4- (7-chloro-1, 3-benzodioxol-5-yl) -1- (3-methoxypyrazino-2-yl) -3-cyclopropyl-1H-pyrazol-5-amine
• A-8 4- (7-Bromo-1,3-benzodioxol-5-yl) -1- (3-ethoxypyrazino-2-yl) -3- (trifluoromethyl) -1H-pyrazol-5-amine
• A-13 1 (3-Methoxypyrazine-2-yl) -3- (trifluoromethyl) -4- [7- (trifluoromethyl) -1,3-benzodioxol-5-yl] -1H-pyrazole-5-amine
• A-14 and A-15 are not listed there explicitly, but fall under the formula (I) and can be analogous to the there produce described method.
• A-14 can be prepared starting from (3,5-dichloro-4-methoxyphenyl) acetonitrile according to the process indicated there.
• the preparation of A-15 is described in detail in the Examples.
• Component B contains one or more compounds of groups (1-1) to (1-25).
• (1-1) Acetylcholinesterase (AChE) inhibitors such as carbamates, e.g. B. alanycarb, aldicarb, bendiocarb, benfuracarb, butocarboxime, butoxycarboxime, carbaryl, carbofuran, carbosulfan, ethiofencarb, fenobucarb, formetanate, furathiocarb, isoprocarb, methiocarb, methomyl, metolcarb, oxamyl, pirimicarb, propoxur, thiodicarb, thiofanox, triazamates, Trimethacarb, XMC and xylylcarb; Bendiocarb, carbaryl, methomyl, promacyl and propoxur are particularly preferred for applications against ectoparasites; or
• Organophosphates e.g. Acephates, azamethiphos, azinphos (-methyl, -ethyl), cadusafos, chloroethoxyfos, chlorfenvinphos, chlormephos, chlorpyrifos (-methyl), coumaphos, cyanophos, demeton-s -methyl, diazinon, dichlorvos / DDVP, dicrotophos, dimethoates , Dimethylvinphos, Disulphon, EPN, Ethion, Ethoprophos, Famphur, Fenamiphos, Fenitrothion, Fenthion, Fosthiazate, Heptenophos, Isofenphos, Isopropyl O- (methoxyaminothio-phosphoryl) salicylate, Isoxathion, Malathion, Mecarbam, Methamidophos, Methidathion, Mevinphos , Monocrotophos, Naled, Om
• GABA-controlled chloride channel antagonists such as organochlorines, e.g. Bromocyclene, chlordane and endosulfan (alpha), heptachlor, lindane, and toxaphene; particularly preferred for applications against ectoparasites are endosulphan (alpha) and lindane; or
• Fiproles phenylpyrazoles
• phenylpyrazoles e.g. Acetoprole, ethiprole, fipronil, pyrafluprole and pyriprole, rizazole; especially, fipronil and pyriprole are preferred here for applications against ectoparasites; or Arylisoxazolines, arylpyrrolines, arylpyrrolidines e.g.
• Sodium channel modulators / voltage dependent sodium channel blockers such as pyrethroids, e.g. Acrinathrin, allethrin (d-cis -trans, d-trans), bifenthrin, bioallethrin, bioallethrin-S-cyclopentenyl, bioresmethrin, cycloprothrin, cyfluthrin (beta), cyhalothrin (gamma, lambda), cypermethrin (alpha), , beta-, theta-, ceta-), cyphenothrin [(IR) -fra's isomers], deltamethrin, dimefluthrin, empenthrin [(EZ) - (IR) isomers], Esfenv alerate, etofenprox, fenpropathrin, fenvalerate, Flucythrinates, flumethrin, fluvalinate, flu
• nicotinergic acetylcholine receptor agonists such as nicotine or neonicotinoids, e.g. Acetamidipid, clothianidin, dinotefuran, imidacloprid, imidaclothiz, nitenpyram, thiacloprid, thiamethoxam;
• nicotine or neonicotinoids e.g. Acetamidipid, clothianidin, dinotefuran, imidacloprid, imidaclothiz, nitenpyram, thiacloprid, thiamethoxam
• Especially preferred for applications against ectoparasites are chlorothianidine, dinotefuran, imidacloprid, nitenpyram, and thiacloprid.
• Allosteric acetylcholine receptor modulators such as spinosyns, e.g. Spinetoram and spinosad; Particular preference may be given here for applications against ectoparasites spinosad and spinetoram.
• (1-6) chloride channel activators such as avermectins / milbemycins, e.g. Abamectin, doramectin, emamectin benzoate, eprinomectin, ivermectin, latidectin, lepimectin, milbemycin oxime, milbemectin, moxidectin, and selamectin; Particularly preferred for applications against ectoparasites are doramectin, eprinomectin, ivermectin, milbemycin oxime, moxidectin and Called selamectin.
• avermectins / milbemycins e.g. Abamectin, doramectin, emamectin benzoate, eprinomectin, ivermectin, latidectin, lepimectin,
• Juvenile hormone analogs e.g. Hydroprene (S), kinoprenes, methoprene (S-); or fenoxycarb; pyriproxyfen; Particular preference may be given here for applications against ectoparasites methoprene (S-) and pyriproxyfen.
• mite growth inhibitors e.g. Clofentezines, diflovidazine, hexythiazox, etoxazoles; Particular preference should be given here for applications against ectoparasites etoxazoles.
• Slo-1 and latrophilin receptor agonists such as cyclic depsipeptides, e.g. B. emodepside and its starting compound PF1022A (known from EP 382173, Compound I); Particular preference may be given here for applications against ectoparasites emodepside.
• Inhibitors of oxidative phosphorylation, ATP disruptors such as diafenthiuron.
• Nicotinergic acetylcholine receptor antagonists such as Bensultap, Cartap (-hydrochloride), thiocylam, and thiosultap (-sodium).
• inhibitors of chitin biosynthesis type 0, such as benzoylureas, eg. Bistrifluron, chlorofluorazuron, diflubenzuron, flucycloxuron, flufenoxuron, hexaflumuron, lufenuron, novaluron, noviflumuron, teflubenzuron and triflumuron; Particular preference may be given here for applications against ectoparasites diflubenzuron, fluazuron, lufenuron and triflumuron.
• Moulting agents such as cyromazines and dicyclanil; Particular preference may be given here for applications against ectoparasites cyromazine and dicyclanil.
• Ecdysone agonists such as diacylhydrazines, e.g. Chromafenozide, Halofenozide, Methoxyfenozide and Tebufenozide.
• octopaminergic agonists such as amitraz, cymiazoles and demiditraz; Particular preference may be given here for applications against ectoparasites amitraz, cymiazoles and demiditraz.
• complex III electron transport inhibitors such as hydramethylnone; acequinocyl; Fluacrypyrim.
• complex I electron transport inhibitors such as from the group of METI acaricides, z. Fenazaquin, Fenpyroximate, Pyrimidifen, Pyridaben, Tebufenpyrad, Tolfenpyrad; particularly preferred for applications against ectoparasites are fenpyroximate, pyrimidifen and tolfenpyrad; (1-20) blockers of the voltage-dependent sodium channel, such as indoxacarb and metaflumizone; Particular preference may be given here for applications against ectoparasites indoxacarb and metaflumizone.
• inhibitors of acetyl-CoA carboxylase such as tetronic acid derivatives, e.g. Spirodiclofen and spiromesifen; or tetramic acid derivatives, e.g. B. spirotetramat.
• complex II electron transport inhibitors such as cyenopyrafen.
• ryanodine receptor effectors such as diamides, e.g. B. Flubendiamide, Chlorantraniliprole (Rynaxypyr), Cyantraniliprole (Cyazypyr) and 3-bromo-N- ⁇ 2-bromo-4-chloro-6- [(1-cyclopropylethyl) carbamoyl] phenyl ⁇ - 1 - (3-chloropyridine-2 -yl) -1 H -pyrazole-5-carboxamide (known from WO2005 / 077934) or methyl 2- [3,5-dibromo-2 - ( ⁇ [3-bromo-1- (3-chloro-2-yne) -new -yl) -1H-pyrazol-5-yl] carbonyl ⁇ amino) benzoyl] - 1, 2-dimethylhydrazinecarboxylate (known from WO2007 / 043677).
• diamides e.g. B
• Suitable synergists for use with ectoparasiticides are MGK264 (N-octylbicycloheptenecarboxamide), piperonyl butoxide (PBO) and verbutin; Particular preference may be given here piperonyl butoxide and MGK264.
• component B (1-2), (1-3), (1-4), (1-5), (1-6), (1-17).
• insecticidal or acaricidal compounds or synergists of component B are endosulphan (alpha), lindane; Fipronil, pyriprole; A 1443 (Example 1 1 -1 from WO 2009/2024541); Allethrin, bioallethrin, permethrin, phenothrin, resmethrin, tetramethrin; cyfluthrin (beta), cyhalothrin (lambda), cypermethrin (alpha, zeta), deltamethrin, fenvalerate, flucythrinates, flumethrin, fluvalinate (tau-); Etofenprox, Silafluofen; Chlothianidine Dinotefuran, Imidacloprid, Nitenpyram, Thiacloprid; Spinosad, spinetoram; Doramectin, eprinomectin, i
• the active substances of group 1-17 have no practically relevant effect on insects. With regard to insect control, therefore, according to one embodiment of the present invention, the active ingredients of group 1-17 are excluded from the above-mentioned embodiments -5 including preferred and particularly preferred embodiments-as component B.
• the active compound combinations according to the invention are very suitable for controlling animal pests in the veterinary field.
• the insecticidal and / or acaricidal action of the active substance combinations according to the invention is improved over the sum of the effects of the individual active substances within components A and B. It is desirable to have an extended spectrum of activity and / or to improve the effect, preferably an unforeseeable true synergistic effect.
• the active compound combinations according to the invention are suitable for use in the field of animal health, ie in the field of veterinary medicine, in the case of good warm-blooded toxicity and good environmental compatibility.
• the active ingredient combinations according to the present invention counteract animal parasites, in particular ectoparasites.
• Ectoparasites are typically and preferably arthropods, especially insects such as flies (stinging and licking), parasitic fly larvae, lice, hair-pieces, feathers, fleas and the like; or acarids such as ticks, for example ticks or leather ticks, or mites such as mange mites, mites, feather mites and the like.
• insects such as flies (stinging and licking), parasitic fly larvae, lice, hair-pieces, feathers, fleas and the like
• acarids such as ticks, for example ticks or leather ticks, or mites such as mange mites, mites, feather mites
• Haematopinus spp. Linognathus spp., Pediculus spp., Phtirus spp., Solenopotes spp .
• specific examples are: Linognathus setosus, Linognathus vituli, Linognathus ovillus, Linognathus oviformis, Linognathus pedalis, Linognathus stenopsis, Haematopinus asini macrocephalus, Haematopinus eurysternus, Haematopinus suis, Pediculus humanus capitis, Pediculus humanus corporis, Phylloera vastatrix, Phthirus pubis, Solenopotes capillatus;
• Nematocerina and Brachycerina z From the order of Diptera and the suborders Nematocerina and Brachycerina z. Eg Aedes spp., Anopheles spp., Culex spp., Simulium spp., Eusimulium spp., Phlebotomus spp., Lutzomyia spp., Culicoides spp., Chrysops spp., Odagmia spp., Wilhelmia spp., Hybomitra spp.
• Atylotus spp. Tabanus spp., Haematopota spp., Philipomyia spp., Braula spp., Musca spp., Hydrotaea spp., Stomoxys spp., Haematobia spp., Morellia spp., Fannia spp., Glossina spp., Calliphora spp , Lucilla spp., Chrysomyia spp., Wohlfahrtia spp., Sarcophaga spp., Oestrus spp.
• Pulex spp. Ctenocephalides spp., Tunga spp., Xenopsylla spp., Ceratophyllus spp .
• specific examples are: Ctenocephalides canis, Ctenocephalides felis, Pulex irritans, Tunga penetrans, Xenopsylla cheopis;
• Ornithonyssus spp. Pneumonyssus spp., Raillietia spp., Pneumonyssus spp., Sternostoma spp., Varroa spp., Acarapis spp .; specific examples are: Argas persicus, Argas reflexus, Ornithodorus moubata, Otobius megnini, Rhipicephalus (Boophilus) microplus, Rhipicephalus (Boophilus) decoloratus, Rhipicephalus (Boophilus) annulatus, Rhipicephalus (Boophilus) calceratus, Hyalomma anatolicum, Hyalomma aegypticum, Hyalomma marginatum, Hyalomma transiens, Rhipicephalus evertsi, Ixodes ricinus, Ixodes hexagonus, Ixodes
• Actinedida Prostigmata
• Acaridida Acaridida
• the active compound combinations according to the invention are suitable for controlling arthropods which infest animals.
• the animals include farm animals such. Cattle, sheep, goats, horses, pigs, donkeys, camels, buffalo, rabbits, chickens, turkeys, ducks, geese, farmed fish, honey bees.
• the animals also include pets - which are also referred to as pets - such.
• dogs, cats, caged birds, aquarium fish and so-called experimental animals such. Hamsters, guinea pigs, rats and mice.
• control means that the active ingredients act by reducing the incidence of the parasite in question in an animal affected by such parasites to harmless levels. More specifically, as used herein, “control” means that the agent kills the subject parasite, inhibits its growth, or inhibits its proliferation.
• the active compounds of the invention when used for the treatment of animals, can be used directly.
• they are used as pharmaceutical compositions which may contain pharmaceutically acceptable excipients and / or adjuvants known in the art.
• the active compounds can be used as shampoo or as suitable, in aerosols or pressureless sprays, eg. For example, pump sprays and nebulizer sprays, applicable formulations can be formulated.
• the active compounds according to the invention can be used as formulations (for example powders, wettable powders, WP), emulsions, emulsifiable concentrates (EC), flowable agents, homogeneous solutions and Suspension concentrates [suspension concentrates, "SC"]) containing the active ingredients in an amount of 1 to 80% by weight, apply directly or after dilution (eg 100 to 10,000 times dilution) or use them as a chemical bath ,
• Empoasca spp. Eriosoma spp., Erythroneura spp., Euscelis bilobatus, Ferrisia spp., Geococcus coffeae, Hieroglyphus spp., Homalodisca coagulata, Hyalopterus arundinis, Icerya spp., Idiocerus spp., Idioscopus spp., Laodelphax st riatellus, Lecanium spp., Lepidosaphes spp., Lipaphis erysimi, Macrosiphum spp., Mahanarva spp., Melanaphis sacchari, Met- Calfiella spp., Metopolophium dirhodum, Monellia costalis, Monelliopsis pecanis, Myzus spp., Nasonovia ribisnigri, Nephotettix spp., Ni
• Cacoecia spp. Caloptilia theivora, Capua reticulana, Carpocapsa pomonella, Carposina niponensis, Cheimatobia brumata, Chilo spp., Choristoneura spp., Clysia ambiguella, Cnaphalocerus spp., Cnephasia spp., Conopomorpha spp., Conotrachelus spp., Copitarsia spp.
• Cydia spp. Dalaca noctuides, Diaphania spp., Diatraea saccharalis, Earias spp., Ecdytolopha aurantium, Elasmopalpus lignosellus, Eidana saccharina, Ephestia kuehniella, Epinotia spp., Epiphyas postvittana, Etiella spp., Eulia spp., Eupoecilia ambiguella, Euproctis Spp., Euxoa spp., Feltia spp., Galleria mellonella, Gracillaria spp., Grapholitha spp., Hedylepta spp., Helicoverpa spp., Heliothis spp., Hofmannophila pseudospretella, Homoeosoma spp., Homona spp., Hyponomeuta padella
• Combination or combination of uses means either that components A and B are formulated in a common preparation and applied together as appropriate, but that the products may also comprise separate preparations for each active substance. Accordingly, all active ingredients in a common preparation or all the active ingredients in separate formulations can be formulated, are also conceivable mixed forms in which a part of the active ingredients together and a part of the active ingredients is formulated separately.
• the reaction mixture is cooled, treated with water and ethyl acetate and filtered through silica gel.
• the organic phase is separated, dried over magnesium sulfate and concentrated.
• the crude product is chromatographed on a silica gel cartridge with a cyclohexane / ethyl acetate gradient. This gives 0.9 g (52.8% of theory) of the title compound as a colorless oil.
• Step 2 2-r3.5-Dichloro-4- (dimethylamino) -hexyl-4.4.4-trifluoro-3-oxobutane-nitrile
• Step 3 (2E) -3-Chloro-2- [3,5-dichloro-4- (dimemylamino) phenyl] -4,4,4-trifluorobut-2-en-nitrile)
• X is the degree of killing, expressed in% of the untreated control, when using the active ingredient A at a rate of m g / ha or in a concentration of m ppm,
• Y means the degree of killing, expressed in% of the untreated control, when using the active ingredient B in an application rate of n g / ha or in a concentration of n ppm
• E means the degree of killing, expressed in% of the untreated control, when using the active compounds A and B at application rates of m and ng / ha or in a concentration of m and n ppm,
• the combination is over-additive in its kill, i. there is a synergistic effect.
• the actually observed kill rate must be greater than the expected kill rate (E) value calculated from the above formula.
• mixtures of A-1: B-11 from 125: 1 to 1:25 showed potent synergistic effects on brown dog tick mortality (Rhipicephalus sanguineus) at 0.288-2.2 ⁇ g / dm 2 of component A- 1 after 24 h and 48 h.
• brown dog tick mortality Rosicephalus sanguineus
• mixtures with component A-1 of A-1: B-18 from 1:25 to 25: 1 showed synergistic effects on the mortality of cat fleas (Ctenocephalides felis) at 0.06-1.4 ⁇ g / dm 2 of Component A-1 after 48 h.
• Example Bl 8 of Table 3 mixtures with component A-1 of A-1: B-18 from 1:25 to 25: 1 showed synergistic effects on the mortality of brown dog ticks (Rhipicephalus sanguineus) at 0.06-1.4 ⁇ g / dm 2 of component A-1 after 48 h.
• Example B-20 of Table 3 mixtures with component A-1 of Al: B-20 from 1:25 to 5: 1 showed synergistic effects on the mortality of cat fleas (Ctenocephalides felis) at 0.06-1.4 ⁇ g / dm 2 of the component A-1 after 24 h.
• Example B-25 of Table 3 blends with Component A-1 of Al: B-25 showed from 1: 125 to 25: 1 synergistic effects on the mortality of cat fleas (Ctenocephalides felis) at 7.2 ⁇ g / dm 2 of component A-1 after 48 h.
• Example B-1 of Table 3 mixtures of A-14: B-1 from 1: 1 to 1: 125 showed synergistic effects on the mortality of cat fleas (Ctenocephalides felis) at 7.2 ⁇ g / dm 2 of component B-1 after 48 H.
• mixtures A-14: B-1 in a ratio of 1: 1 to 1:25 were synergistically effective at 7.2 and 1.4 ⁇ g / dm 2 of component B-1 after 24 h.
• Example B-11 no insecticides could be expected in the contact test procedure Be detected effect, since the drug class of such amidines in veterinary indications no practically relevant insecticidal activity. Accordingly, under the test conditions, the insecticidal activity of component A-14 in combinations with Bl l remained virtually unchanged.
• mixtures with component B-II mixtures of A-14: B-1 1 from 25: 1 to 1: 125 showed synergistic effects on brown dog tick mortality (Rhipicephalus sanguineus) at 0.288-2.2 ⁇ g / dm 2 of component A- 14 after 48 h.
• Example B-20 of Table 3 mixtures with component A-14 of A-14: B-20 of 1: 125 to 5: 1 showed synergistic effects on the mortality of cat fleas (Ctenocephalides felis) at 0.28-2.2 ⁇ g / dm 2 of component A-14 after 24 h and 48 h.
• Example B-29 of Table 3 blends with Component A-14 of A-14: B-29 of 1: 5 to 125: 1 showed synergistic effects on the effect on cat fleas (Ctenocephalides felis) at 1.44-2.2 ⁇ g / dm 2 Component A - 14 after 24 h.
• Example AI 5 For Example B-1 of Table 3, mixtures of A-15: B-1 of 5: 1 to 1: 125 showed synergistic effects on the mortality of cat fleas (Ctenocephalides felis) at 1.4 ⁇ g / dm 2 of component B. - 1 after 48 h.
• mixtures of A-15 B-1 1 from 125: 1 to 1:25 showed synergistic effects on brown dog tick mortality (Rhipicephalus sanguineus) at 0.288-2.2 ⁇ g / dm 2 of component A- 1 after 48 h.
• Example B-18 of Table 3 mixtures with A-15 component of A-15: B-18 from 1:25 to 25: 1 showed synergistic effects on the mortality of cat fleas (Ctenocephalides felis) at 0.28-2.2 ⁇ g / dm 2 of component A-15 after 24 h.
• Example B-18 of Table 3 blends with component A-15 under the test conditions showed no change in activity against the brown dog tick.
• Example B-20 of Table 3 mixtures with component A-15 of A-15: B-20 of 1:25 and higher showed synergistic effects on the mortality of cat fleas (Ctenocephalides felis) at 0.06-2.2 ⁇ g / dm 2 of the component A- 15 after 24 h.
• Example B-25 of Table 3 mixtures with component A-15 of A-15: B-25 from 1: 125 to 25: 1 showed synergistic effects on the mortality of cat fleas (Ctenocephalides felis) at 0.28-2.2 ⁇ g / dm 2 of component A-15 after 48 h.
• mixtures A-15: B-25 in a ratio of 1: 125 to 5: 1 were synergistically effective at 1.44-180 ⁇ g / dm 2 of component A-15 after 24 and 48 h.
• Example B-27 of Table 3 mixtures with A-15 component of A-15: B-27 from 1:25 to 25: 1 showed synergistic effects on the mortality of cat fleas (Ctenocephalides felis) at 1.44-2.2 ⁇ g / dm 2 of component A-15 after 48 h.
• B-27 In the brown dog tick (Rhipicephalus sanguineus) mixtures A - 1: B -27 in the ratio 25: 1 to 1: 125 showed synergistic effects on the mortality at 0.06 - 7.2 ⁇ g / dm 2 of the component Al after 48 h.
• Example B-29 of Table 3 blends with A-15 component of A-15: B-29 of 1: 5 to 1: 125 showed synergistic effects on cat flea mortality (Ctenocephalides felis) at 7.2 ⁇ g / dm 2 of the component A- 15 after 24 h.
• Example B-37 of Table 3 blends with A-15 component of A-15: B-37 from 1: 125 to 125: 1 showed synergistic effects on brown dog tick mortality (Rhipicephalus sanguineus) at 7.2-180 ⁇ g / dm 2 of component A-15 after 48 h.

Applications Claiming Priority (2)

Publications (1)

Family

ID=45476470

Family Applications (1)

Country Status (25)

Families Citing this family (3)

Family Cites Families (40)

• 2010
  • 2010-12-21 DE DE102010063691A patent/DE102010063691A1/de not_active Withdrawn
• 2011
  • 2011-12-19 JP JP2013545280A patent/JP6018580B2/ja not_active Expired - Fee Related
  • 2011-12-19 CN CN201180068136.0A patent/CN103442569B/zh not_active Expired - Fee Related
  • 2011-12-19 AU AU2011347551A patent/AU2011347551B2/en not_active Ceased
  • 2011-12-19 RU RU2013133704/13A patent/RU2013133704A/ru not_active Application Discontinuation
  • 2011-12-19 EP EP11807897.1A patent/EP2654425A2/de not_active Withdrawn
  • 2011-12-19 US US13/995,958 patent/US9066945B2/en not_active Expired - Fee Related
  • 2011-12-19 NZ NZ612221A patent/NZ612221A/en not_active IP Right Cessation
  • 2011-12-19 WO PCT/EP2011/073280 patent/WO2012084852A2/de active Application Filing
  • 2011-12-19 BR BR112013015952-9A patent/BR112013015952A2/pt not_active Application Discontinuation
  • 2011-12-19 KR KR1020137018518A patent/KR20140034743A/ko not_active Application Discontinuation
  • 2011-12-19 MX MX2013006866A patent/MX2013006866A/es unknown
  • 2011-12-19 MY MYPI2013002297A patent/MY164916A/en unknown
  • 2011-12-19 CA CA2822080A patent/CA2822080A1/en not_active Abandoned
  • 2011-12-20 TW TW100147255A patent/TWI593685B/zh not_active IP Right Cessation
  • 2011-12-20 UY UY0001033822A patent/UY33822A/es not_active Application Discontinuation
  • 2011-12-21 AR ARP110104847A patent/AR084509A1/es unknown
• 2013
  • 2013-06-17 CO CO13144324A patent/CO6751235A2/es unknown
  • 2013-06-19 GT GT201300157A patent/GT201300157A/es unknown
  • 2013-06-19 DO DO2013000143A patent/DOP2013000143A/es unknown
  • 2013-06-19 CR CR20130303A patent/CR20130303A/es unknown
  • 2013-06-19 CL CL2013001794A patent/CL2013001794A1/es unknown
  • 2013-06-20 CU CU2013000081A patent/CU20130081A7/es unknown
  • 2013-06-20 NI NI201300056A patent/NI201300056A/es unknown
  • 2013-06-20 EC ECSP13012706 patent/ECSP13012706A/es unknown

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events